Richard Steinhart - Mar 14, 2023 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role: Chief Financial Officer
Signature: /s/ Javier Rodriguez, as attorney-in-fact for Richard Steinhart
Stock symbol: BTAI
Transactions as of: Mar 14, 2023
Transactions value $: -$40,638
Form type: 4
Date filed: 3/16/2023, 06:02 PM
Previous filing: Jul 1, 2022
Next filing: May 5, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BTAI	Common Stock	Options Exercise		+2.08K	+138.93%		3.58K	Mar 14, 2023	Direct	F1
transaction	BTAI	Common Stock	Sale	-$40.6K	-2.08K	-58.15%	$19.50	1.5K	Mar 15, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BTAI	Restricted Stock Units	Options Exercise	$0	-2.08K	-25%	$0.00	6.25K	Mar 14, 2023	Common Stock	2.08K		Direct	F1, F3
transaction	BTAI	Restricted Stock Units	Award	$0	+9K		$0.00	9K	Mar 15, 2023	Common Stock	9K		Direct	F1, F4
transaction	BTAI	Stock Option (Right to Buy)	Award	$0	+32K		$0.00	32K	Mar 15, 2023	Common Stock	32K	$19.60	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 23, 2022.
F3	On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
F4	The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
F5	The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of March 15, 2023 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.